Literature DB >> 2472085

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.

H L Messmore1, B Griffin, J Fareed, E Coyne, J Seghatchian.   

Abstract

Heparin, low molecular weight heparins, and heparinoids were studied for their ability to inhibit the aggregation of platelets by various agonists and for their ability to adhere to collagen. Heparin was a very effective inhibitor of aggregation with collagen and with ristocetin as it was with adhesion to collagen. The heparinoids showed little effect on aggregation or adhesion. Heparan sulfate and pentosan polysulfate did show slight inhibitory activity against collagen aggregation and adhesion and both interacted with the antibody induced by heparin therapy. It is of interest that dermatan sulfate and the pentasaccharide were almost inert in these experiments, and are unlikely to induce bleeding by inhibition of platelet function. It is highly probable that interference with the interaction of von Willebrand factor with platelets and collagen is a major mechanism for bleeding in the heparinized patient.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472085     DOI: 10.1111/j.1749-6632.1989.tb22505.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients.

Authors:  M T Nurmohamed; H R Büller; J W ten Cate
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

2.  Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.

Authors:  K Krupinski; M Basic-Micic; E Lindhoff; H K Breddin
Journal:  Blut       Date:  1990-11

Review 3.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations.

Authors:  M T Nurmohamed; H ten Cate; J W ten Cate
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 5.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 6.  Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.

Authors:  Neil A Reynolds; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.

Authors:  Jawed Fareed; Debra Hoppensteadt; Jeanine Walenga; Omer Iqbal; Qing Ma; Walter Jeske; Taqdees Sheikh
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Fondaparinux: use in thromboprophylaxis of acute medical patients.

Authors:  Sohita Dhillon; Greg L Plosker
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.